Neurosciences encompasses a broad range of research from the molecular (e.g. aptamer research) to clinical (e.g. research into concussion from sports).
Our goal is to be internationally recognized in 3 areas (neuro-oncology, dementia and neurodegeneration and molecular psychiatry). We have a bench to bedside approach capitalizing on our quite unique staff profile ranging from basic biomedical scientists through pharmaceutics to clinicians.
We also focus on collaborations with our local charities and a network of researchers and clinicians across the world.
We have a significant local impact in our neuro-oncology research. One strand of our Molecular Psychiatry group is research into legal highs and this research has had an impact on the government drug policy. Our Dementia and Neurodegeneration group is funded by the company.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
23
Jul 2026
Congenital heart disease is the most common birth defect, affecting approximately 1 in 100 babies born each year. One of the many causes for this disorder is having only one functional copy of the gene TBX5, instead of two healthy copies, inherited from parents.
23
Jul 2026
Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a predominant cause of chronic liver disease, underscoring the demand for accessible, non-invasive diagnostic tools.
23
Jul 2026
Researchers from Carnegie Mellon University's School of Computer Science, the University of Pittsburgh School of Medicine and the University of Washington shed new light on Alzheimer's disease that could point to new directions for treatment.
23
Jul 2026
Researchers have discovered that the human brain undergoes widespread age-related changes in genome regulation beginning in midlife that may help explain why aging is the greatest risk factor for neurodegenerative diseases such as Alzheimer's.